TY - JOUR
T1 - Regurgitant Volume/Left Ventricular End-Diastolic Volume Ratio
T2 - Prognostic Value in Patients With Secondary Mitral Regurgitation
AU - Namazi, Farnaz
AU - van der Bijl, Pieter
AU - Fortuni, Federico
AU - Mertens, Bart J.A.
AU - Kamperidis, Vasileios
AU - van Wijngaarden, Suzanne E.
AU - Stone, Gregg W.
AU - Narula, Jagat
AU - Ajmone Marsan, Nina
AU - Vahanian, Alec
AU - Delgado, Victoria
AU - Bax, Jeroen J.
N1 - Funding Information:
Dr. Kamperidis received a European Society of Cardiology training grant, a European Association of Cardiovascular Imaging research grant, a Hellenic Cardiological Society training grant, and a Hellenic Foundation of Cardiology research grant. The Department of Cardiology of Leiden University Medical Centre received grants from Biotronik, Bioventrix, Bayer, Medtronic, Abbott Vascular, Boston Scientific Corporation, Edwards Lifesciences, and GE Healthcare. Drs. Ajmone Marsan and Bax received speaker fees from Abbott Vascular. Dr. Delgado received speaker fees from Abbott Vascular, Medtronic, MSD, Edwards Lifesciences, and GE Healthcare. Dr. Stone has received speaker fees or other honoraria from Cook, Terumo, Qool Therapeutics, and Orchestra Biomed; has served as a consultant to Valfix, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA Pharmaceuticals, Vectorious Medical Technologies, Reva, and Matrizyme Pharma; and has equity/options from Ancora, Qool Therapeutics, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, MedFocus family of funds, and Valfix Medical. Dr. Vahanian is a consultant for CardioValve. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Funding Information:
Dr. Kamperidis received a European Society of Cardiology training grant, a European Association of Cardiovascular Imaging research grant, a Hellenic Cardiological Society training grant, and a Hellenic Foundation of Cardiology research grant. The Department of Cardiology of Leiden University Medical Centre received grants from Biotronik, Bioventrix, Bayer, Medtronic, Abbott Vascular, Boston Scientific Corporation, Edwards Lifesciences, and GE Healthcare. Drs. Ajmone Marsan and Bax received speaker fees from Abbott Vascular. Dr. Delgado received speaker fees from Abbott Vascular, Medtronic, MSD, Edwards Lifesciences, and GE Healthcare. Dr. Stone has received speaker fees or other honoraria from Cook, Terumo, Qool Therapeutics, and Orchestra Biomed; has served as a consultant to Valfix, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA Pharmaceuticals, Vectorious Medical Technologies, Reva, and Matrizyme Pharma; and has equity/options from Ancora, Qool Therapeutics, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, MedFocus family of funds, and Valfix Medical. Dr. Vahanian is a consultant for CardioValve. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2021 American College of Cardiology Foundation
PY - 2021/4
Y1 - 2021/4
N2 - Objectives: The purpose of this study was to investigate the prognostic implications of the ratio of mitral regurgitant volume (RVol) to left ventricular (LV) end-diastolic volume (EDV) in patients with significant secondary mitral regurgitation (MR). Background: Quantification of secondary MR remains challenging, and its severity can be over- or underestimated when using the proximal isovelocity surface area method, which does not take LV volume into account. This limitation can be addressed by normalizing mitral RVol to LVEDV. Methods: A total of 379 patients (mean age 67 ± 11 years; 63% male) with significant (moderate and severe) secondary MR were divided into 2 groups according to the RVol/EDV ratio: RVol/EDV ≥20% (greater MR/smaller EDV) and <20% (smaller MR/larger EDV). The primary endpoint was all-cause mortality. Results: During median (interquartile range) follow-up of 50 (26 to 94) months, 199 (52.5%) patients died. When considering patients receiving medical therapy only, patients with RVol/EDV ratio ≥20% tended to have higher mortality rates than those with RVol/EDV ratio <20% (5-year estimated rates 24.1% vs. 18.4%, respectively; p = 0.077). Conversely, when considering the entire follow-up period including mitral valve interventions, patients with a higher RVol/EDV ratio (≥20%) had lower rates of all-cause mortality compared with patients with RVol/EDV ratio <20% (5-year estimated rates 39.0% vs. 44.8%, respectively; p = 0.018). On multivariable analysis, higher RVol/EDV ratio (per 5% increment as a continuous variable) was independently associated with lower all-cause mortality (0.93; p = 0.023). Conclusions: In patients with significant secondary MR treated medically, survival tended to be lower in those with a higher RVol/EDV ratio. Conversely, a higher RVol/EDV ratio was independently associated with reduced all-cause mortality.
AB - Objectives: The purpose of this study was to investigate the prognostic implications of the ratio of mitral regurgitant volume (RVol) to left ventricular (LV) end-diastolic volume (EDV) in patients with significant secondary mitral regurgitation (MR). Background: Quantification of secondary MR remains challenging, and its severity can be over- or underestimated when using the proximal isovelocity surface area method, which does not take LV volume into account. This limitation can be addressed by normalizing mitral RVol to LVEDV. Methods: A total of 379 patients (mean age 67 ± 11 years; 63% male) with significant (moderate and severe) secondary MR were divided into 2 groups according to the RVol/EDV ratio: RVol/EDV ≥20% (greater MR/smaller EDV) and <20% (smaller MR/larger EDV). The primary endpoint was all-cause mortality. Results: During median (interquartile range) follow-up of 50 (26 to 94) months, 199 (52.5%) patients died. When considering patients receiving medical therapy only, patients with RVol/EDV ratio ≥20% tended to have higher mortality rates than those with RVol/EDV ratio <20% (5-year estimated rates 24.1% vs. 18.4%, respectively; p = 0.077). Conversely, when considering the entire follow-up period including mitral valve interventions, patients with a higher RVol/EDV ratio (≥20%) had lower rates of all-cause mortality compared with patients with RVol/EDV ratio <20% (5-year estimated rates 39.0% vs. 44.8%, respectively; p = 0.018). On multivariable analysis, higher RVol/EDV ratio (per 5% increment as a continuous variable) was independently associated with lower all-cause mortality (0.93; p = 0.023). Conclusions: In patients with significant secondary MR treated medically, survival tended to be lower in those with a higher RVol/EDV ratio. Conversely, a higher RVol/EDV ratio was independently associated with reduced all-cause mortality.
KW - prognosis
KW - regurgitant volume
KW - secondary mitral regurgitation
UR - http://www.scopus.com/inward/record.url?scp=85090199215&partnerID=8YFLogxK
U2 - 10.1016/j.jcmg.2020.06.032
DO - 10.1016/j.jcmg.2020.06.032
M3 - Article
C2 - 32828778
AN - SCOPUS:85090199215
SN - 1936-878X
VL - 14
SP - 730
EP - 739
JO - JACC: Cardiovascular Imaging
JF - JACC: Cardiovascular Imaging
IS - 4
ER -